France Biotech Announces Launch of HealthTech Investor Day in Paris on June 25th, 2019

For the first time in France, there will be a unique gathering of French and European health innovation companies, international investors and leading pharmaceutical firms. This exceptional business opportunity for HealthTech entrepreneurs will include:

- One-on-one meetings with entrepreneurs, investors, and pharmaceutical groups
- Roundtables centered on health and investment issues

Paris, February 19, 2019 - France Biotech, the main professional association representing French health entrepreneurs, will gather the entire innovation ecosystem by launching the HealthTech Investor Day [http://www.htid-paris.com](http://www.htid-paris.com) (HTID®), an international event which will be held in Paris on June 25, 2019. This exclusive event will bring together French and European HealthTech leaders (biotech, medtech, e-health, etc.), large pharmaceutical companies and international investors in health innovation.

This first edition will take place on Tuesday June 25 at the Peninsula Hotel, in the heart of Paris, under the High Patronage of Mr Emmanuel MACRON, President of French Republic and with the partnership of key players from the health innovation ecosystem including BDC Lifesciences, Bpifrance, Business France, Sofinnova Partners, Financière Arbevel, LEEM (Les Entreprises du Médicament), as well as pharmaceutical companies, such as Ipsen and Servier. The French competitiveness clusters, LIR (Association des Laboratoires Internationaux de Recherche), Euronext, Société Générale, ODDO BHF, EBE (European Biopharmaceutical Enterprises), EuropaBio, EIT Health and the IREFI (Institute for French-Italian Economic Relations) will also support the event. Various other partners and supports are expected to join France Biotech to promote the HealthTech sector.

Nearly 1,500 SMEs and start-up companies strive to invent tomorrow’s medicine in France. With the HealthTech Investor Day (HTID®), France Biotech aims to strengthen this promising and dynamic ecosystem by turning Paris into the European stronghold for funding innovative health technologies. France Biotech has chosen to organize the event in Paris in an effort to support French and European companies through their second round of financing, which can be difficult to achieve.

The HTID® is intended for publicly listed and private companies from the HealthTech sector (biotech, medtech, AI and e-health), whose market capitalization is at least €20 million (for listed companies) or whose drug candidates are currently undergoing a Phase II study (for privately held biotech firms). This event is dedicated to mature HealthTech companies that have already raised significant funds. For medtech companies, medical devices must have already obtained the CE marking in Europe or FDA (Food and Drug Administration) approval in the United States. The challenge is the same for all companies: to spark the interest of leading investors in the sector.

French competitiveness clusters (large and small companies, research laboratories and educational institutions working together to develop synergies and innovative joint projects,) will relay a call for expressions of interest with the organizational support of Medicen Paris Région, the competitiveness cluster for innovative health technologies in the Paris region.
The HTID® will be a twofold event: **It will feature one-on-one meetings with health innovative entrepreneurs, investors, and leading pharmaceutical firms in addition to roundtables focused on economic and political issues related to tomorrow’s medicine.** The details about the roundtables and their moderators will be announced subsequently.

“France Biotech is pleased to give European HealthTech companies a unique opportunity to meet international investors in France. This HealthTech Investor Day is a testament of our commitment to support health innovation SMEs and start-up companies, which have managed to get off the ground, but are struggling to find new investors to make their innovations available to patients. By organizing this day in France, we want to highlight the dynamism and value of the French and European companies striving to invent tomorrow’s medicine,” said **Maryvonne Hiance, Chairman of France Biotech.**

**About France Biotech**

Created in 1997, France Biotech is a French nonprofit that brings together the country’s leading innovative health companies and their expert partners (investors, lawyers, research institutes, competitiveness clusters, etc.). Its core mission is to promote health innovation in France and help the sector’s start-up companies and SMEs to become successful organizations, capable of rapidly developing new therapeutic solutions. France Biotech, which championed the creation of the French Young Innovative Company (JEI) status in 2004, is advocating for the innovative health sector to be recognized as a cutting-edge industry. France Biotech is chaired by Maryvonne Hiance, and has more than 200 members. [www.france-biotech.fr](http://www.france-biotech.fr)

**Press contacts**

**ALIZE RP - Europe**
Caroline Carmagnol / Najette Chaib / Julie Petrich-Combe
francebiotech@alizerp.com
+336 64 18 99 59 / +336 47 38 90 04 / +336 43 19 09 29

**RooneyPartners LLC – North America**
Marion Janic / Kate Barrette
mjanic@rooneyco.com / kbarrette@rooneyco.com
+1.212.223.4017 / +1.212.223.0561

**France Biotech**
Maryvonne Hiance
Chairman
mhiance@france-biotech.org

For More information on HTID®:
Contact Sophie Villedieu
sophie.villedieu@france-biotech.org